Table 2.

Recommendations for disease activity measurement in juvenile idiopathic arthritis (JIA)-related uveitis

	L	S	Agreement (%)	References
4. There should be good communication between the ophthalmologist and the paediatric rheumatologist concerning changes in disease activity treatment changes and responsibility for treatment monitoring.	3	C	100	71
5. There is a need to develop shared outcome measures to help guide decisions on systemic treatment.	4	D	100
6. At present, there is no validated biomarker to follow the activity of uveitis.	2A	B	100	4 21 29 31 32 37 41 46 72–76
7. At present, no widely accepted definition of inactive disease for JIA-related uveitis is available. The goal of treating JIA-associated uveitis should be no cells in the anterior chamber. The presence of macular and/or disk oedema, ocular hypotony and rubeosis iridis may require anti-inflammatory treatment even in the absence of AC cells.	2B	B	100	4 69 78
8. We recommend 2 years of inactive disease off topical steroids before reducing systemic immunosuppression (both DMARDs and biological therapies).	3	C	92	67

Agreement indicates the % of experts that agreed on the recommendation during the final voting round of the consensus meeting.

1A, meta-analysis of cohort studies; 1B, meta-analysis of case–control studies; 2A, cohort studies; 2B, case–control studies; 3, non-comparative descriptive studies; 4, expert opinion; A, based on level 1 evidence; B, based on level 2 or extrapolated from level 1; C, based on level 3 or extrapolated from level 1 or 2; D, based on level 4 or extrapolated from level 3 or 4 expert opinion. DMARD, disease-modifying anti rheumatic drugs; L, level of evidence; S, strength of evidence.